Functional Characterization of ABCA3 Genomic Variants
Functional Characterization of ABCA3 Genomic Variants
批准号:
10561718
负责人:
Jennifer Wambach
金额:
$51.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-02-15 至 2025-01-31
关键词:
A549ATF6 geneATP phosphohydrolaseATP-Binding Cassette TransportersAffectAllelesAzithromycinBiological AssayBreathingCRISPR/Cas technologyCell LineCell SurvivalCellular Metabolic ProcessCellular StressChildChildhoodCloningCystic Fibrosis Transmembrane Conductance RegulatorDegradation PathwayDevelopmentDiameterDiseaseEndoplasmic ReticulumEpithelial CellsEpitheliumFDA approvedFluorescenceGene MutationGenesGeneticGenetic RecombinationGreen Fluorescent ProteinsHumanHydroxychloroquineImpairmentIn VitroIndividualInfantInterstitial Lung DiseasesLabelLecithinLentivirusLiposomesLocationLungLung TransplantationLysosomesMediatingMedicalMembraneMendelian disorderMutagenesisMutationNeonatal Respiratory DistressParentsPathogenicityPathway interactionsPatientsPharmaceutical PreparationsPhospholipidsPhysiologicalPrivatizationProtease InhibitorProteinsPulmonary SurfactantsRNA SplicingRegulator GenesRespiratory FailureSiteSteroidsStressSystemTertiary Protein StructureTestingToxic effectUbiquitinVX-809VariantVesiclealveolar lamellar bodyalveolar type II cellcystic fibrosis patientsfunctional genomicsgenetic variantgenome editinggenomic platformindividual responseindividualized medicinemembermodel developmentmulticatalytic endopeptidase complexmutantpulmonary functionrespiratory distress syndromescreeningsmall moleculestable cell linesurfactantsurfactant functionsurfactant productionsurfactant replacementtargeted treatmenttraffickinguptakevirulence gene
中文摘要
项目总结
新生儿呼吸窘迫综合征(RDS)传统上归因于发育调节障碍
肺表面活性物质的生产。然而,对患有致命性RDS的足月儿的研究导致了这一发现
基因控制的功能性表面活性物质生产中断。罕见或私有,双等位基因,致病
三磷酸腺苷结合盒转运体A3基因(ABCA3)的变异是最常见的单基因引起的
足月儿新生儿RDS与儿童间质性肺疾病(儿童)ABCA3转运磷脂
穿过肺泡II型细胞的板层小体限制膜,是包装功能性
表面活性剂。致病的ABCA3变异体编码(1)细胞内转运中断,(2)ATP-
酶介导的,磷脂转运到板层小体,也可能(3)激活细胞内压力和
破坏肺功能的降解途径。目前的治疗方法(表面活性物质替代、类固醇、
阿奇霉素和羟氯喹)是非特异性和无效的。肺移植,为期5年
存活率约为50%,仍是受影响的婴儿和儿童进行性呼吸衰竭的唯一治疗方法。
囊性纤维化致病变异型患者的变异型特异性治疗进展
跨膜电导调节基因(CFTR)是ABC转运蛋白超家族(ABCC7)的成员,
可以为ABCA3的变种特异性疗法的开发提供一个模型,尽管校正者可能会
特定于基因和变异的。
该方案的前提是开发一个可扩展的、功能齐全的机械式基因组学平台
ABCA3变异体的特性及小分子校正子化合物的筛选和鉴定
在人体、肺上皮、生理相关细胞系中。具体来说,我们将使用克隆衍生的A549
稳定表达单个ABCA3致病变异体的细胞系,用于(1)基于荧光的功能分析,
(2)变异体特异性致病细胞降解途径激活的特征,以及(3)筛选
FDA批准的化合物用于拯救变种编码的ABCA3胞内错误和致病
激活降解途径以检验变种编码的ABCA3错配和
细胞应激和降解途径的致病激活可以从机制上进行表征
并且可以用FDA批准的小分子进行纠正。
这些研究将为可扩展的、具有功能的、与生理相关的基因组学提供原则证据
为患有ABCA3缺乏症的婴儿和儿童发现变种特异性疗法的平台。此外,这一点
基因多功能系统可以被改造和扩展,以发现针对其他疾病患者的靶向治疗
破坏肺表面活性物质功能或肺上皮细胞代谢的单基因疾病。
英文摘要
PROJECT SUMMARY
Neonatal respiratory distress syndrome (RDS) is traditionally attributed to developmentally regulated disruption
of pulmonary surfactant production. However, studies of term infants with lethal RDS have led to the discovery
of genetically regulated disruption of functional surfactant production. Rare or private, biallelic, pathogenic
variants in the ATP binding cassette transporter A3 gene (ABCA3) are the most common monogenic causes of
neonatal RDS in term infants and childhood interstitial lung disease (chILD). ABCA3 transports phospholipids
across the lamellar body limiting membrane in alveolar type II cells and is required for packaging of functional
surfactant. Pathogenic ABCA3 variants encode (1) disruption of intracellular trafficking, (2) impairment of ATP-
ase mediated, phospholipid transport into the lamellar body, and may also (3) activate intracellular stress and
degradation pathways that disrupt lung function. Current treatments (surfactant replacement, steroids,
azithromycin, and hydroxychloroquine) are non-specific and ineffective. Lung transplantation, with a 5 year
survival of ~50%, remains the only treatment for progressive respiratory failure in affected infants and children.
Development of variant-specific therapies for patients with pathogenic variants in the cystic fibrosis
transmembrane conductance regulator gene (CFTR), a member of the ABC transporter superfamily (ABCC7),
can provide a model for development of variant-specific therapies for ABCA3, although correctors will likely be
gene- and variant-specific.
The premise of this proposal is to develop a scalable, functional genomics platform for mechanistic
characterization of ABCA3 variants and for compound screening and identification of small molecule correctors
in a human, pulmonary epithelial, physiologically-relevant cell line. Specifically, we will use clonally derived A549
cell lines that stably express individual ABCA3 pathogenic variants for (1) fluorescence-based, functional assays,
(2) characterization of variant-specific, pathogenic cellular degradation pathway activation, and (3) screening of
FDA-approved compounds for rescue of variant-encoded ABCA3 intracellular mistrafficking and pathogenic
degradation pathway activation to test hypothesis that variant-encoded ABCA3 mistrafficking and
pathogenic activation of cellular stress and degradation pathways can be mechanistically characterized
and can be corrected with FDA-approved small molecules.
These studies will provide proof of principle for a scalable, functional, physiologically-relevant genomics
platform to discover variant-specific therapies for infants and children with ABCA3 deficiency. Additionally, this
genetically versatile system can be adapted and extended to discover targeted therapies for patients with other
monogenic diseases that disrupt surfactant function or pulmonary epithelial cell metabolism.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURFACTANT PATHWAY GENE VARIANTS AMONG INFANTS WITH RESPIRATORY DISTRESS SYNDROME
-
批准号:8293039
-
项目类别:
-
资助金额:$12.55万
-
财政年份:2011
-
负责人:Jennifer Wambach
-
依托单位:
SURFACTANT PATHWAY GENE VARIANTS AMONG INFANTS WITH RESPIRATORY DISTRESS SYNDROME
-
批准号:8190268
-
项目类别:
-
资助金额:$12.55万
-
财政年份:2011
-
负责人:Jennifer Wambach
-
依托单位:
SURFACTANT PATHWAY GENE VARIANTS AMONG INFANTS WITH RESPIRATORY DISTRESS SYNDROME
-
批准号:8500434
-
项目类别:
-
资助金额:$12.55万
-
财政年份:2011
-
负责人:Jennifer Wambach
-
依托单位:
Variation in SP-C and Key UPR Genes among Infants with Respiratory Distress
-
批准号:7394675
-
项目类别:
-
资助金额:$2.29万
-
财政年份:2008
-
负责人:Jennifer Wambach
-
依托单位: